Lymphomas — Internal Medicine · Expert Reference Guide

Internal Medicine · Clinical Specialties

How it begins

Guía de referencia exhaustiva sobre la biología, clasificación, diagnóstico, estadificación y tratamiento de los linfomas de Hodgkin y no Hodgkin. Nivel de subespecialidad en Hematología-Oncología.

What it covers

1. Introduction and Epidemiology
2. · Risk Factors
3. Lymphocyte Ontogeny and Pathogenic Basis
4. · B Cell Development — The Germinal Center as an Oncogenic Epicenter
5. · Signaling Pathways Frequently Altered in Lymphomas
6. WHO 2022 Classification of Lymphoid Tumors
7. · Main Changes in the WHO Classification 2022 vs 2016
8. Hodgkin lymphoma
9. · Classification of Hodgkin's Lymphoma
10. · Reed-Sternberg Cell Biology
11. · Clinical Presentation
12. · Diagnosis
13. · Staging and Prognostic Factors
14. · Treatment of Hodgkin's Lymphoma
15. DLBCL — Diffuse Large B Cell Lymphoma
16. · Molecular Subtypes — Cell of Origin (COO)
17. · DLBCL Double-Hit and Triple-Hit (HGBL)
18. · IPI — International Prognostic Index
19. · DLBCL Treatment
20. Follicular Lymphoma
21. · Biology and Genetics
22. · Classification by Histological Grade
23. · FLIPI and FLIPI-2 Prognostic Index
24. · Treatment of Follicular Lymphoma
25. Mantle, Burkitt and Marginal Zone Cell Lymphoma
26. · Mantle Cell Lymphoma (MCL)
27. · Burkitt's lymphoma
28. · Marginal Zone Lymphomas (MZL)
29. Peripheral T and NK lymphomas
30. · Main Entities
31. Staging — Lugano System 2014
32. · Deauville Scale for Response Evaluation with PET-CT
33. · Lugano Stadium Modifiers
34. Diagnosis — Comprehensive Algorithm
35. · Clinical Presentation — Warning Signs
36. · Biopsy — The First Step Diagnosis
37. · Immunohistochemistry — Diagnostic Panels
38. · Molecular and Cytogenetic Studies
39. · Evaluation of Extension of Disease
40. Treatment — General Principles and Current Therapies
41. · Anti-CD20: The Pillar of B Lymphoma Treatment
42. · Conventional Chemotherapy — The Fundamental Schemes
43. · New Therapeutic Targets
44. · CAR-T Cells — Adoptive Immunotherapy
45. · Bispecific Antibodies — The New Frontier
46. · Hematopoietic Cell Transplantation (ASCT / Allo-SCT)
47. Emergencies in Lymphomas
48. · Tumor Lysis Syndrome (TLS)
49. · Superior Vena Cava Syndrome (SVCS)
50. · Epidural Spinal Compression (ESC)
51. · Secondary Hemophagocytic Lymphohistiocytosis (HLH)
52. · Hypercalcemia
53. Special Contexts, Follow-up and Late Toxicities
54. · Lymphomas in Patients with HIV
55. · Post-Transplant Lymphomas (PTLD)
56. · Lymphoma during Pregnancy
57. · Lymphoma in the Elderly
58. · Monitoring of Patients in Remission and Late Toxicities
59. · Lugano 2014 Response Criteria — Summary